CN1216636C - 肽缓释组合物 - Google Patents
肽缓释组合物 Download PDFInfo
- Publication number
- CN1216636C CN1216636C CN971975485A CN97197548A CN1216636C CN 1216636 C CN1216636 C CN 1216636C CN 971975485 A CN971975485 A CN 971975485A CN 97197548 A CN97197548 A CN 97197548A CN 1216636 C CN1216636 C CN 1216636C
- Authority
- CN
- China
- Prior art keywords
- weight
- compositions
- deslorelin
- gnrh agonist
- lecithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 title description 2
- 239000010936 titanium Substances 0.000 title description 2
- 229910052719 titanium Inorganic materials 0.000 title description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims abstract description 51
- 239000000556 agonist Substances 0.000 claims abstract description 47
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims abstract description 32
- 108700025485 deslorelin Proteins 0.000 claims abstract description 32
- 229960005408 deslorelin Drugs 0.000 claims abstract description 32
- 241000282472 Canis lupus familiaris Species 0.000 claims abstract description 27
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 21
- 229940067606 lecithin Drugs 0.000 claims abstract description 21
- 235000010445 lecithin Nutrition 0.000 claims abstract description 21
- 239000000787 lecithin Substances 0.000 claims abstract description 21
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 7
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 4
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims abstract 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 22
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 14
- 108010069236 Goserelin Proteins 0.000 claims description 12
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical group C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 12
- 229960002913 goserelin Drugs 0.000 claims description 12
- 229960004824 triptorelin Drugs 0.000 claims description 11
- 108010037003 Buserelin Proteins 0.000 claims description 10
- 108010050144 Triptorelin Pamoate Proteins 0.000 claims description 10
- 229960002719 buserelin Drugs 0.000 claims description 10
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 10
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 10
- 108010000817 Leuprolide Proteins 0.000 claims description 8
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 8
- 229960004338 leuprorelin Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 claims description 7
- 108010021717 Nafarelin Proteins 0.000 claims description 7
- 108700020746 histrelin Proteins 0.000 claims description 7
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 claims description 7
- 108700025096 meterelin Proteins 0.000 claims description 7
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 claims description 7
- 229960002333 nafarelin Drugs 0.000 claims description 7
- 201000001514 prostate carcinoma Diseases 0.000 claims description 7
- 230000001850 reproductive effect Effects 0.000 claims description 7
- 201000008275 breast carcinoma Diseases 0.000 claims description 6
- 229940036197 supprelin Drugs 0.000 claims description 6
- 208000004145 Endometritis Diseases 0.000 claims description 5
- 230000003054 hormonal effect Effects 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 206010020112 Hirsutism Diseases 0.000 claims description 3
- 208000029312 Muscular tumor Diseases 0.000 claims description 3
- 241000097929 Porphyria Species 0.000 claims description 3
- 208000010642 Porphyrias Diseases 0.000 claims description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 3
- 208000031295 Animal disease Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 201000000484 premenstrual tension Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940122985 Peptide agonist Drugs 0.000 abstract description 5
- 206010060862 Prostate cancer Diseases 0.000 abstract description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 3
- 239000003163 gonadal steroid hormone Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 229930193551 sterin Natural products 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 45
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 41
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 41
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 22
- 239000007943 implant Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 15
- 229960003604 testosterone Drugs 0.000 description 11
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 229930182833 estradiol Natural products 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 206010062767 Hypophysitis Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000051 antiandrogen Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 235000012438 extruded product Nutrition 0.000 description 3
- 230000003328 fibroblastic effect Effects 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 239000000745 gonadal hormone Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- -1 phosphocholine ester Chemical class 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YGGIRYYNWQICCP-LDRBRYNMSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-methylamino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydrox Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 YGGIRYYNWQICCP-LDRBRYNMSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 2
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 229960003822 lutrelin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000004706 scrotum Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- PLZNPHDJGFDNRM-UHFFFAOYSA-M O.[Na+].[O-][PH2]=O Chemical compound O.[Na+].[O-][PH2]=O PLZNPHDJGFDNRM-UHFFFAOYSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- WNMUQCZSGYECJO-WCCKRBBISA-N acetic acid;(2s)-pyrrolidine-2-carboxamide Chemical compound CC(O)=O.NC(=O)[C@@H]1CCCN1 WNMUQCZSGYECJO-WCCKRBBISA-N 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000002434 gonadorelin derivative Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 210000004368 gonadotroph Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 229960002193 histrelin Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001719 neurosecretory cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002199 spermatogenetic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 206010046459 urethral obstruction Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO2035A AUPO203596A0 (en) | 1996-08-30 | 1996-08-30 | Hormone therapy |
| AUP02035 | 1996-08-30 | ||
| AUPO4107A AUPO410796A0 (en) | 1996-12-06 | 1996-12-06 | Method of treating benign prostatic hyperplasia |
| AUP04107 | 1996-12-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1228707A CN1228707A (zh) | 1999-09-15 |
| CN1216636C true CN1216636C (zh) | 2005-08-31 |
Family
ID=25645254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN971975485A Expired - Fee Related CN1216636C (zh) | 1996-08-30 | 1997-09-01 | 肽缓释组合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6337318B1 (de) |
| EP (1) | EP1007080B1 (de) |
| JP (1) | JP3860841B2 (de) |
| CN (1) | CN1216636C (de) |
| AT (1) | ATE359805T1 (de) |
| CA (1) | CA2264562C (de) |
| DE (1) | DE69737635T2 (de) |
| DK (1) | DK1007080T3 (de) |
| ES (1) | ES2285737T3 (de) |
| HK (1) | HK1022275A1 (de) |
| NZ (1) | NZ334236A (de) |
| WO (1) | WO1998008533A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ334236A (en) * | 1996-08-30 | 2000-06-23 | Peptech Ltd | Composition comprising GnRH, lecithin and stearin |
| US8052982B2 (en) | 1998-07-20 | 2011-11-08 | Peptech Animal Health Pty Limited | Bioimplant formulation comprising lecithin and stearin |
| CA2336879C (en) * | 1998-07-20 | 2010-06-01 | Peptech Limited | Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients |
| JP2004512369A (ja) * | 2000-10-30 | 2004-04-22 | ユニバーシティ・オブ・チューリッヒ | 尿失禁の治療のためのｇｎｒｈアナログ |
| US7776310B2 (en) * | 2000-11-16 | 2010-08-17 | Microspherix Llc | Flexible and/or elastic brachytherapy seed or strand |
| CA2451187C (en) | 2001-06-22 | 2012-08-14 | Southern Biosystems, Inc. | Zero-order prolonged release coaxial implants |
| US20030186892A1 (en) * | 2002-03-28 | 2003-10-02 | Rajneesh Taneja | Enhancement of endogenous gonadotropin production |
| CN1688696A (zh) * | 2002-09-18 | 2005-10-26 | 蒙特利尔大学医疗中心 | Ghrh类似物 |
| MXPA05003318A (es) * | 2002-09-27 | 2005-09-12 | Zentaris Gmbh | Forma de administracion para peptidos farmaceuticamente activos con liberacion sostenida y metodo para la produccion de los mismos. |
| US20040224000A1 (en) * | 2003-05-05 | 2004-11-11 | Romano Deghenghi | Implants for non-radioactive brachytherapy of hormonal-insensitive cancers |
| JP2007517042A (ja) | 2003-12-30 | 2007-06-28 | デュレクト コーポレーション | 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント |
| US8062652B2 (en) * | 2004-06-17 | 2011-11-22 | Endo Pharmaceuticals Solutions Inc. | Compositions and methods for treating precocious puberty |
| WO2006071208A1 (en) * | 2004-12-23 | 2006-07-06 | Durect Corporation | Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of a gnrh |
| JP4584331B2 (ja) * | 2005-03-11 | 2010-11-17 | インデバス ファーマシューティカルズ、インク． | オクトレオチドの放出制御製剤 |
| US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
| US8227408B2 (en) * | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
| US8882747B2 (en) * | 2005-11-09 | 2014-11-11 | The Invention Science Fund I, Llc | Substance delivery system |
| GB0616111D0 (en) * | 2006-06-16 | 2006-09-20 | Ardana Bioscience Ltd | Agents, methods and uses |
| EP2139447A2 (de) * | 2007-03-20 | 2010-01-06 | Harold Brem | Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung |
| CA2683517A1 (en) * | 2007-04-23 | 2008-10-30 | Bayer Schering Pharma Aktiengesellschaft | Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases |
| RU2521291C2 (ru) * | 2008-06-25 | 2014-06-27 | Эндо Фармасьютикалз Солюшнз Инк. | Имплантат октреотида, содержащий высвобождающее вещество |
| US8071537B2 (en) * | 2008-06-25 | 2011-12-06 | Endo Pharmaceuticals Solutions Inc. | Implantable device for the sustained release of a polypeptide |
| IL312316A (en) | 2012-09-26 | 2024-06-01 | Aragon Pharmaceuticals Inc | Antiandrogens for the treatment of castration-resistant prostate cancer without metastases |
| WO2015158823A1 (de) | 2014-04-16 | 2015-10-22 | Veyx-Pharma Gmbh | Veterinärpharmazeutische zusammensetzung und deren verwendung |
| KR20200070334A (ko) | 2017-10-16 | 2020-06-17 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
| AU2019275409B2 (en) | 2018-05-24 | 2024-08-15 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| CN111971026A (zh) | 2018-05-24 | 2020-11-20 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| KR102249104B1 (ko) * | 2019-04-30 | 2021-05-07 | (주)인벤티지랩 | 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법 |
| WO2024003291A1 (en) | 2022-06-30 | 2024-01-04 | Virbac | Deslorelin use in chemical castration of a non-human mammal related to pk/pd interaction |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4256737A (en) * | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
| DE3413608A1 (de) | 1984-04-11 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung |
| IT1191608B (it) * | 1985-02-01 | 1988-03-23 | Zambon Spa | Composizione farmaceutica e forme farmaceutiche che la contengono |
| JPH0662441B2 (ja) | 1986-02-18 | 1994-08-17 | 花王株式会社 | 抗腫瘍物質徐放性製剤 |
| IT1213464B (it) * | 1986-07-25 | 1989-12-20 | Riccardo Casero | Forma farmaceutica per la somministrazione enterica di acido etodolico o di suoi sali, in miscela con eccipienti. |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5039660A (en) * | 1988-03-02 | 1991-08-13 | Endocon, Inc. | Partially fused peptide pellet |
| US5372996A (en) * | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
| US5256649A (en) * | 1989-05-23 | 1993-10-26 | Elf Sanofi | Cosmetic composition against aging of the skin |
| US5180434A (en) | 1991-03-11 | 1993-01-19 | United Solar Systems Corporation | Interfacial plasma bars for photovoltaic deposition apparatus |
| US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| WO1993007833A1 (en) | 1991-10-21 | 1993-04-29 | Peptide Technology Limited | Biocompatible implant for the timing of ovulation in mares |
| WO1993015722A1 (en) * | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| KR950007873A (ko) | 1993-09-20 | 1995-04-15 | 후꾸하라 요시하루 | 생리 활성 물질 지속 방출형의 의약 제제 |
| JPH09507233A (ja) * | 1993-12-29 | 1997-07-22 | マトリクス ファーマスーティカル，インコーポレイティド | 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物 |
| US6136781A (en) * | 1995-04-28 | 2000-10-24 | Takeda Chemical Industries, Ltd. | LH-RH receptor antagonists |
| AUPN366795A0 (en) * | 1995-06-20 | 1995-07-13 | Peptide Technology Limited | Formulation for preventing reproductive function |
| NZ334236A (en) * | 1996-08-30 | 2000-06-23 | Peptech Ltd | Composition comprising GnRH, lecithin and stearin |
-
1997
- 1997-09-01 NZ NZ334236A patent/NZ334236A/en not_active IP Right Cessation
- 1997-09-01 ES ES97936524T patent/ES2285737T3/es not_active Expired - Lifetime
- 1997-09-01 WO PCT/AU1997/000560 patent/WO1998008533A1/en active IP Right Grant
- 1997-09-01 US US09/242,635 patent/US6337318B1/en not_active Expired - Lifetime
- 1997-09-01 DK DK97936524T patent/DK1007080T3/da active
- 1997-09-01 CN CN971975485A patent/CN1216636C/zh not_active Expired - Fee Related
- 1997-09-01 DE DE69737635T patent/DE69737635T2/de not_active Expired - Lifetime
- 1997-09-01 AT AT97936524T patent/ATE359805T1/de not_active IP Right Cessation
- 1997-09-01 JP JP51105398A patent/JP3860841B2/ja not_active Expired - Fee Related
- 1997-09-01 EP EP97936524A patent/EP1007080B1/de not_active Expired - Lifetime
- 1997-09-01 CA CA2264562A patent/CA2264562C/en not_active Expired - Lifetime
-
2000
- 2000-02-29 HK HK00101268A patent/HK1022275A1/xx not_active IP Right Cessation
-
2001
- 2001-11-26 US US09/991,714 patent/US6777386B2/en not_active Expired - Lifetime
-
2004
- 2004-03-25 US US10/808,504 patent/US7309689B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP3860841B2 (ja) | 2006-12-20 |
| US20040180832A1 (en) | 2004-09-16 |
| ES2285737T3 (es) | 2007-11-16 |
| EP1007080B1 (de) | 2007-04-18 |
| ATE359805T1 (de) | 2007-05-15 |
| US7309689B2 (en) | 2007-12-18 |
| CA2264562A1 (en) | 1998-03-05 |
| EP1007080A1 (de) | 2000-06-14 |
| NZ334236A (en) | 2000-06-23 |
| US6337318B1 (en) | 2002-01-08 |
| US6777386B2 (en) | 2004-08-17 |
| CN1228707A (zh) | 1999-09-15 |
| EP1007080A4 (de) | 2006-01-18 |
| WO1998008533A1 (en) | 1998-03-05 |
| US20020052320A1 (en) | 2002-05-02 |
| DK1007080T3 (da) | 2007-07-30 |
| HK1022275A1 (en) | 2000-08-04 |
| DE69737635D1 (de) | 2007-05-31 |
| DE69737635T2 (de) | 2008-01-03 |
| JP2000517307A (ja) | 2000-12-26 |
| CA2264562C (en) | 2012-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1216636C (zh) | 肽缓释组合物 | |
| JP3313113B2 (ja) | 雌馬の排卵制御用生体適合性インプラント | |
| US20050276854A1 (en) | Bioimplant formulation | |
| JP2003517014A (ja) | 即放性および徐放性成分を含有する医薬インプラントおよび投与方法 | |
| US20110142901A1 (en) | Sustained release composition | |
| CN1145496C (zh) | 用于肽释放的新型组合物 | |
| AU713413B2 (en) | Sustained peptide-release formulation | |
| Désévaux et al. | Characterization of subcutaneous Contramid® implantation: host response and delivery of a potent analog of the growth hormone-releasing factor | |
| US8052982B2 (en) | Bioimplant formulation comprising lecithin and stearin | |
| AU755443C (en) | Bioimplant formulation | |
| AU1843899A (en) | Novel formulation for peptide release | |
| AU2005249143A1 (en) | Sustained release composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: New South Wales Australia Patentee after: Alana Medical Ltd. Address before: New South Wales Australia Patentee before: Peptech Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20090123 Address after: New South Wales, Australia Patentee after: Tektronix pypo animal health Co.,Ltd. Address before: New South Wales Australia Patentee before: Alana Medical Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: PIPETEC ANIMALS HEALTH CO., LTD. Free format text: FORMER OWNER: ARANA MEDICAL CO., LTD. Effective date: 20090123 |
|
| C56 | Change in the name or address of the patentee |
Owner name: ARANA MEDICAL CO., LTD. Free format text: FORMER NAME: PIPETEC CO., LTD. |
|
| ASS | Succession or assignment of patent right |
Owner name: VIC (AUSTRALIA) LTD. Free format text: FORMER OWNER: PEPROTECH ANIMAL HEALTH CO., LTD. Effective date: 20121113 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20121113 Address after: New South Wales Australia Patentee after: Vic (Australia) Ltd. Address before: New South Wales, Australia Patentee before: Tektronix pypo animal health Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050831 Termination date: 20160901 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |